Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–228 of 228 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication of Injection Clear all
Completed Phase 3 Interventional

Treatment of Diabetic Macular Edema: Triamcinolone Injections Vs. Laser Photocoagulation

NCT00105404
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema, DME
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:07 AM EDT
Enrolling by invitation Phase 4 Interventional

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections

NCT07456826
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
Interventions
Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Sham Subconjunctival Injection, Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
Drug · Procedure
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 20, 2026, 6:07 AM EDT
Not listed Not applicable Interventional

The Effect of Preemptive Levator Ani Injections on Pain After Pelvic Reconstructive Surgery

NCT04428320
View directory record Official record
Conditions
Pelvic Floor Prolapse, Surgery, Pain, Postoperative
Interventions
Pelvic floor injection
Procedure
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 20, 2026, 6:07 AM EDT
Completed Phase 3 Interventional Results available

Gadobutrol Enhanced MRA of the Renal Arteries

NCT01344460
View directory record Official record
Conditions
Renal Artery Obstruction
Interventions
Gadobutrol (Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 20, 2026, 6:07 AM EDT
Not listed Phase 2Phase 3 Interventional

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

NCT00479596
View directory record Official record
Conditions
Overactive Bladder
Interventions
Botox
Drug
Lead sponsor
Urological Sciences Research Foundation
Other
Eligibility
40 Years to 90 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 20, 2026, 6:07 AM EDT
Completed Not applicable Interventional

Long Term Safety of Cooling Anesthesia for Intravitreal Injection

NCT03956797
View directory record Official record
Conditions
Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Recens Cooling Anesthesia Device
Device
Lead sponsor
Recens Medical, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Reno, Nevada • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 20, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 20, 2026, 6:07 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 20, 2026, 6:07 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

NCT05063734
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level, Aflibercept
Drug
Lead sponsor
Oxurion
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Huntington Beach, California • Pasadena, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 20, 2026, 6:07 AM EDT
Completed Phase 1 Interventional

Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders

NCT00101764
View directory record Official record
Conditions
Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:07 AM EDT
Completed Phase 2 Interventional

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

NCT02552277
View directory record Official record
Conditions
Diabetic Nephropathies, Peripheral Nervous System Diseases
Interventions
PDA-002, Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Garden Grove, California • Orange, California • Orlando, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 20, 2026, 6:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 20, 2026, 6:07 AM EDT